S. Agarwala

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
S. Agarwala, Sanjiv S. Agarwala, S. S. Agarwala, Sanjiv S Agarwala, S S Agarwala, Sanjiv Agarwala, S Agarwala
Publication record
290 papers · 21,155 citations · H-index 61

PAPERS

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
20251 citationsauthor #5
Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients.
20253 citationsauthor #7
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
20233 citationsauthor #2
Systemic Therapy for Melanoma: ASCO Guideline Update
2023141 citationsauthor #2
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
202330 citationsauthor #10
Systemic Therapy for Melanoma: ASCO Guideline Update Q and A.
202312 citationsauthor #6
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
20226 citationsauthor #2
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)
20221 citationsauthor #1
Tilsotolimod exploits the TLR9 pathway to promote antigen presentation and Type 1 IFN signaling in solid tumors: A Multicenter International Phase I/II trial (ILLUMINATE-101).
20227 citationsauthor #4
Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist
20210 citationsauthor #13
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
20207 citationsauthor #3
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
2020114 citationsauthor #3
Abstract No. 509 Oncolytic immunotherapy of hepatic tumors with intralesional rose bengal disodium
20200 citationsauthor #9
Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma
20200 citationsauthor #1
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019
20204 citationsauthor #2
Percutaneous hepatic injection of rose bengal disodium (PV-10) in metastatic uveal melanoma.
20207 citationsauthor #5
1125P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Results in patients naïve to immune checkpoint blockade
20204 citationsauthor #1
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019
20200 citationsauthor #2
Diagnosis of Stage IV Melanoma
20205 citationsauthor #2
1123P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade
20207 citationsauthor #7
Systemic Therapy for Melanoma: ASCO Guideline.
2020226 citationsauthor #11
Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.
20194 citationsauthor #6
A phase I clinical trial investigating the therapeutic cancer vaccine UV1 in combination with pembrolizumab as first-line treatment of patients with malignant melanoma
20190 citationsauthor #1
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
201914 citationsauthor #2
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
201996 citationsauthor #19
Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.
201918 citationsauthor #1
Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
201934 citationsauthor #9
Management of metastatic cutaneous melanoma: updates in clinical practice
201935 citationsauthor #4
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
201918 citationsauthor #2
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
201817 citationsauthor #8
Hairy Leukoplakia
20180 citationsauthor #4
Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma
20185 citationsauthor #9
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update
2018218 citationsauthor #4
Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma.
20189 citationsauthor #3
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
20187 citationsauthor #3
Uncovering oncologists’ gaps and attitudes toward biosimilars: Impact of a two-phase educational program.
20181 citationsauthor #4
Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey.
20180 citationsauthor #2
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
20183 citationsauthor #220
Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
20186 citationsauthor #9
KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC).
20185 citationsauthor #9
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
20180 citationsauthor #220
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.
201868 citationsauthor #7
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
201849 citationsauthor #3
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.
201824 citationsauthor #1
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
201865 citationsauthor #4
410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
20178 citationsauthor #11
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
201718 citationsauthor #2
Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)
20170 citationsauthor #8
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
201729 citationsauthor #18
Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma
20177 citationsauthor #11
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
2017146 citationsauthor #4
ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.
201722 citationsauthor #10
Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients.
20178 citationsauthor #3
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
20170 citationsauthor #18
378OSubgroup analysis of a phase II multicenter trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in unresectable or metastatic melanoma patients
20171 citationsauthor #3
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy
2017113 citationsauthor #29
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
201742 citationsauthor #1
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
201748 citationsauthor #3
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
201664 citationsauthor #2
Intralesional treatment for advanced melanoma: what's on the horizon?
20160 citationsauthor #1
Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
20164 citationsauthor #3
Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).
20162 citationsauthor #4
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
201620 citationsauthor #849
Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.
201620 citationsauthor #3
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
201693 citationsauthor #8
Phase 1b Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy (CRT)-Induced Oral Mucositis (OM) in Patients (pts) With Oral Cavity or Oropharyngeal Carcinoma (OCC)
20162 citationsauthor #4
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM
201632 citationsauthor #7
Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
201625 citationsauthor #11
Intralesional rose bengal for treatment of melanoma
20163 citationsauthor #1
The Role of Intralesional Therapies in Melanoma.
201614 citationsauthor #1
Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.
201619 citationsauthor #3
Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
20166 citationsauthor #5
Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
201611 citationsauthor #10
Phase 1b/2a Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy–Induced Oral Mucositis (OM) in Patients With Oral Cavity or Oropharyngeal Carcinoma (OCC)
20164 citationsauthor #5
Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases
2016140 citationsauthor #10
Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma.
20166 citationsauthor #3
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
2016842 citationsauthor #10
Intralesional rose bengal for stage III and IV melanoma
20160 citationsauthor #1
Future perspectives in melanoma research
201610 citationsauthor #2
P-116Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver
20152 citationsauthor #4
Rose Bengal for melanoma treatment: will it translate to the clinic?
20150 citationsauthor #1
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
20152,241 citationsauthor #10
Practical Approaches to Immunotherapy in the Clinic.
20159 citationsauthor #1
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
201572 citationsauthor #5
Intralesional therapy for advanced melanoma: promise and limitation
201541 citationsauthor #1
The Expanding Role of Immunotherapy in Melanoma--Introduction.
20151 citationsauthor #1
Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
201543 citationsauthor #11
300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
20150 citationsauthor #10
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
201526 citationsauthor #9
Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone
20155 citationsauthor #11
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
20159 citationsauthor #10
Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).
20157 citationsauthor #8
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
201581 citationsauthor #16
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
20151,483 citationsauthor #21
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
20152,591 citationsauthor #10
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
2014203 citationsauthor #4
Melanoma adjuvant therapy.
20146 citationsauthor #2
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
2014142 citationsauthor #2
1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.
201411 citationsauthor #194
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
201427 citationsauthor #9

TIMELINE

1974 10 citations

1989 2 citations

1990 0 citations

1993 1 citations

1994 24 citations

1995 35 citations

1996 89 citations

1997 1 citations

1998 315 citations

1999 890 citations

2000 406 citations

2001 1,113 citations

2002 498 citations

2003 123 citations

2004 1,632 citations

2005 425 citations

2006 454 citations

2007 437 citations

2008 692 citations

2009 1,239 citations

2010 279 citations

2011 484 citations

2012 620 citations

2013 1,216 citations

2014 537 citations

2015 6,611 citations

2016 1,317 citations

2017 442 citations

2018 477 citations

2019 219 citations

2020 374 citations

2021 0 citations

2022 14 citations

2023 186 citations

2025 4 citations

S. Agarwala

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT